Friday, 20 Sep 2019

You are here

Safety Concerns Offset the Modest Improvements of Tanezumab in Osteoarthritis

JAMA reports that although tanezumab is modestly effective in moderate to severe osteoarthritis (knee or hip), with statistically significant improvements in pain and physical function, the tanezumab (TNZ) treated patients had more joint safety events and total joint replacements than patients treated with placebo.

Tanezumab is an investigational humanized monoclonal antibody that binds and inhibits nerve growth factor (NGF) and is being developed by Pfizer and Eli Lilly and Company.

In this trial a total of 698 hip or knee OA patients (refreactory to standard analgesic therapies) were randomized to receive placebo or 2 different dosing regimens of subcutaneous tanezumab given at 8-week intervals. The co–primary end points were the 16 week change in Western Ontario and McMasters Universities Osteoarthritis Index (WOMAC) Pain (0-10), WOMAC Physical Function (0-10) and patient global assessment of osteoarthritis (PGA-OA) (1-5) scores.

The mean age was 60.8 years; 65.1% women), and 84% completed the trial.  The results from baseline to 16 weeks are shown below:

DoseTNZ 2.5mgTNZ 2.5/7.5PBO


7.1 to 3.6 (P=0.01)*

7.3 to 3.6 (P=0.002)*7.3 to 4.4
WOMAC Function7.2 to 3.7 (P=0.007)*7.4 to 3.6 (P<0.001)*7.4 to 4.5
PGA-OA3.4 to 2.4 (P=0.01)*3.5 to 2.4 (P=0.004)*3.5 to 2.7

*p Values compared to placebo

Rapidly progressive OA occurred only in tanezumab-treated patients (2.5 mg: n = 5, 2.2%; 2.5/5 mg: n = 1, 0.4%).

The incidence of total joint replacements was 8 (3.5%), 16 (6.9%), and 4 (1.7%) in the tanezumab, 2.5 mg; tanezumab, 2.5/5 mg; and placebo groups, respectively.

Although statistically significant, the risk of rapidly advancing joint damage with this nerve growth factor inhibitor questions the practicality and utility of tanezumab for treatment of osteoarthritis.



The author has no conflicts of interest to disclose related to this subject

Add new comment

More Like This

Need for Pre-operative Hyperglycemia Testing Prior to Total Joint Replacement

JAMA reports on a large Medicare cohort study showing that amongst patients undergoing total joint replacement (TJR), preoperative HbA1c testing was performed in 26% to 43% of patients with diabetes and in only 5% of those without diabetes. Importantly research has shown that an elevated HbA1c level is associated with postoperative complications.

Weight Loss Cuts Hospital Stays for Obese TKA Patients

Morbidly obese patients who lost 20 lbs before total knee arthroplasty (TKA) cut their hospital stays by about 1 day, and were 76% less likely to have an extended hospital stay, research showed. 

High-Dose Vitamin D: No Help for Bone Health

Vitamin D might not be much help for strengthening bones among healthy adults without osteoporosis, Canadian researchers reported, even at doses far higher than recommended daily allowances. In a clinical trial assessing three levels of daily vitamin D supplementation -- 400 IU, 4,000 IU, and 10,000 IU -- radial volumetric bone mineral density was significantly lower among those (ages 55-70) taking higher doses for 3 years, according to Steven Boyd, PhD, of the University of Calgary in Canada, and colleagues.

Osteoporosis Tx: Good for Bones, but Not for Cutting Death Risk

Osteoporosis treatments were not linked with reduced overall mortality, according to a meta-analysis of placebo-controlled trial data.

Looking at data from 38 clinical trials, there was no significant association found between all drug-based osteoporosis treatments and overall mortality rate (risk ratio 0.98, 95% CI 0.91-1.05), reported Steven Cummings, MD, of the San Francisco Coordinating Center, and colleagues.

Bisphosphonate Use Associated with Reduced Mortality

The Journal of Bone and Mineral Research (JBMR) has published a report showing that a reduction in the rate of bone loss by nitrogen bisphosphonates was associated with a 40% lower mortality risk.

Accelerated bone loss has been shown to be an independent predictor of mortality risk, but the relationship between bisphosphonates, bone loss, and mortality is unknown.